Preview

Злокачественные опухоли

Расширенный поиск

ПЕРСОНАЛИЗИРОВАННАЯ ТЕРАПИЯ В ОНКОЛОГИИ: НАСТОЯЩЕЕ И БУДУЩЕЕ

https://doi.org/10.18027/2224-5057-2012-2-105-109

Полный текст:

Аннотация

.

Об авторе

М. Ю. Федянин
Отделение клинической фармакологии и химиотерапии РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Список литературы

1. K.N.Mendes, D. Nicorici, D. Cogdell et al. Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. J. Proteome Res., 2007, 6 (7), pp 2753–2767.

2. Y.J. Kim, Y.S. Ha, S.K. Kim et al. Gene signatures for the prediction of response to bacillus Calmette-Guérin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 2010;16:2131-2137.

3. M.Gerlinger, . A.J. Rowan, S. Horswell et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.

4. Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63.

5. L.V. Sequist, B. A. Waltman, D. Dias-Santagata et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3, 75ra26 (2011).

6. Jung-min Lee . Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies. J Clin Oncol 30:5s, 2012 (suppl; abstr 2545).

7. Philippe Bedard. A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. J Clin Oncol 30:5s, 2012 (suppl; abstr 3003).

8. Qian CN, Min HQ, Lin HL, et al. Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470). J Laryngol Otol 1998;112:849-53.

9. Qian CN, Min HQ, Lin HL, et al. Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/ HK1. Oncology 1999;57:36-41.

10. Hui EP, Ma BB, King AD, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011;22:1280-7.

11. Houk B.E., Bello C.L., Michaelson M.D. et al. A population pharmacokinetic/pharmaco-dynamic (PK/PD) analysis of exposure–response for sunitinib in metastatic renal cell carcinoma (mRCC). Presented at the 14th European Cancer Conference, 23–27. Barcelona: Spain September 2007.

12. Demetri G.D., Casale P.G., Bello C. et al. A population pharmacokinetic/pharmaco-dynamic (PK/PD) meta-analysis of sunitinib in patients with gastrointestinal stromal tumour. Presented at the 19th International Congress on Anti-Cancer Treatment, 5–8. Paris, France February 2008.

13. G.R. Blumenschein. Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 30:5s, 2012 (suppl; abstr 5592).

14. C. Xue, S. Yat-sen. A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 30:5s, 2012 (suppl; abstr 5538).

15. Kutter C., Svoboda P. Meeting report: miRNA, siRNA, piRNA. Knowns of the unknown. RNA Biology 5:4, 181-188; October/November/December 2008.

16. J.S. Duncan, M.C. Whittle, K.Nakamura et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307–321, April 13, 2012

17. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. Journal of Clinical Oncology 2008;26(25):4217–9.

18. R.E. Kast. Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamineaugmented ramelteon, atibant, imiquimod peritoneal lavage, and plerixafor. Journal of Cancer Therepeutics & Research 2012.


Для цитирования:


Федянин М.Ю. ПЕРСОНАЛИЗИРОВАННАЯ ТЕРАПИЯ В ОНКОЛОГИИ: НАСТОЯЩЕЕ И БУДУЩЕЕ. Злокачественные опухоли. 2012;2(2):105-109. https://doi.org/10.18027/2224-5057-2012-2-105-109

For citation:


. . Malignant tumours. 2012;2(2):105-109. (In Russ.) https://doi.org/10.18027/2224-5057-2012-2-105-109

Просмотров: 234


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)